Chimeric Antigen Receptor T Cell Therapies For Multiple Myeloma

T cells expressing the car used in this work.

Chimeric antigen receptor t cell therapies for multiple myeloma.

Dimopoulos 8 paulo lucio 9 joan bladé 10 michel delforge 11 roman. Multiple myeloma mm is a nearly always incurable malignancy of plasma cells so new approaches to treatment are needed. In the past few years chimeric antigen receptor car modified t cell therapy for mm. Multiple myeloma mm is the second most common hematologic malignancy and remains incurable despite the advent of numerous new drugs such as proteasome inhibitors pis immunomodulatory agents imids and monoclonal antibodies.

5 6 18 20 cars are. B cell maturation antigen bcma is expressed in most cases of mm. We conducted the first in humans clinical trial of chimeric antigen receptor car t cells targeting bcma. Chimeric antigen receptor t cell therapy for multiple myeloma.

Therapies with novel mechanisms of action are needed for multiple myeloma mm. Cars are artificial fusion proteins that incorporate an antigen recognition domain and t cell signaling domains. Disease settings where clinical evaluation of car t cell therapy has been reported advanced relapse refractory disease. There is an unmet need to develop novel therapies for refractory relapsed mm.

In this phase 1 study involving patients with relapsed or refractory multiple myeloma we administered bb2121 as a single infusion at doses of 50 10 6 150 10 6 450 10 6 or 800 10. A consensus statement from the european myeloma network philippe moreau 1 pieter sonneveld 2 mario boccadoro 3 gordon cook 4 ma victoria mateos 5 hareth nahi 6 hartmut goldschmidt 7 meletios a. 5 6 18 t cells expressing a car can specifically recognize a targeted antigen which is an advantage of car t cells over nonspecific cellular therapies such as allogeneic hematopoietic stem cell transplantation. Potential and currently studied settings for the use of car chimeric antigen receptor t cell therapy in the management of multiple myeloma through the natural history of the disease.

Chimeric antigen receptors cars are fusion. B cell maturation antigen bcma is a validated target for chimeric antigen receptor car t cell therapy in multiple myeloma mm.